![Hugh Jackson](https://cdn.zonebourse.com/static/resize/768/576//static/images/insiders/unknown.png)
Hugh Jackson
Direktor/Vorstandsmitglied bei Actimed Therapeutics Ltd.
Aktive Positionen von Hugh Jackson
Unternehmen | Position | Beginn | Ende |
---|---|---|---|
Actimed Therapeutics Ltd.
![]() Actimed Therapeutics Ltd. Miscellaneous Commercial ServicesCommercial Services Actimed Therapeutics Ltd. is a British clinical stage specialty pharmaceutical company that focuses on bringing innovation to the treatment of muscle wasting disorders. Actimed is based in Ascot, UK. Actimed's lead product, ACM-001 (S-pindolol), targets multiple biological pathways that drive cachexia and has generated promising proof of concept data in a phase II clinical trial in patients with non-small cell lung cancer (NSCLC) and colorectal cancer (CRC). The company is currently preparing for further clinical studies of cachexia in these two cancer types. The company was founded in 2017 by Stefan D. Anker and Andrew Justin Stewart Coats, two world-leading physicians in muscle wasting research, together with Yann Colardelle, a professional in communications and medical education. | Direktor/Vorstandsmitglied | - | - |
Finanzdirektor/CFO | - | 19.10.2023 |
Karriereverlauf von Hugh Jackson
Statistik
International
Vereinigtes Königreich | 2 |
Operativ
Director/Board Member | 1 |
Director of Finance/CFO | 1 |
Sektoral
Commercial Services | 2 |
Besetzte Positionen
Aktive
Inaktive
Börsennotierte Unternehmen
Private Unternehmen
Unternehmensverbindungen
Private Unternehmen | 1 |
---|---|
Actimed Therapeutics Ltd.
![]() Actimed Therapeutics Ltd. Miscellaneous Commercial ServicesCommercial Services Actimed Therapeutics Ltd. is a British clinical stage specialty pharmaceutical company that focuses on bringing innovation to the treatment of muscle wasting disorders. Actimed is based in Ascot, UK. Actimed's lead product, ACM-001 (S-pindolol), targets multiple biological pathways that drive cachexia and has generated promising proof of concept data in a phase II clinical trial in patients with non-small cell lung cancer (NSCLC) and colorectal cancer (CRC). The company is currently preparing for further clinical studies of cachexia in these two cancer types. The company was founded in 2017 by Stefan D. Anker and Andrew Justin Stewart Coats, two world-leading physicians in muscle wasting research, together with Yann Colardelle, a professional in communications and medical education. | Commercial Services |
- Börse
- Insiders
- Hugh Jackson
- Erfahrung